Marksans Pharma submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the Bombay Stock Exchange and National Stock Exchange on August 4, 2026. The filing, made pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, provides a comprehensive overview of the company’s environmental, social, and governance (ESG) performance on a standalone basis. The report underscores the company’s global operational footprint, noting that exports constitute 100% of its total turnover, while detailing key financial metrics including a turnover of ₹1,341.47 crores and a net worth of ₹1,652.31 crores.

The submission was authorized by Harshavardhan Panigrahi, Company Secretary, and covers the period from April 1, 2025, to March 31, 2026. Marksans Pharma operates through two plants and two offices nationally, alongside an international presence involving subsidiaries in the UK, US, Europe, Canada, and Australasia. The company’s core business activities involve the research, manufacturing, and sales of generic, specialty, over-the-counter (OTC), and prescription pharmaceutical products across therapeutic areas such as pain management, oncology, and cardiovascular systems.

Governance and Material Risks

The report identifies corporate governance, business ethics, and regulatory compliance as material risks and opportunities. Marksans Pharma states that strong governance practices are critical to maintaining stakeholder confidence and avoiding regulatory sanctions. The company has implemented a Board and Committee structure to oversee these risks, supported by whistleblower mechanisms and grievance redressal policies. Mr. Mark Saldanha, Chairman & Managing Director, oversees sustainability-related issues. The company reported no complaints regarding unethical practices or human rights violations during the fiscal year.

Environmental and Operational Sustainability

Marksans Pharma detailed its environmental management practices, including waste management and energy efficiency initiatives. The company has implemented a mechanism for Zero Liquid Discharge, where Effluent Treatment Plant (ETP) treated water is reused for gardening purposes. Hazardous waste is disposed of through authorized vendors compliant with the Environment Protection Act 1986. The report highlights an initiative to separate Sewage Treatment Plants (STP) from ETPs to reduce chemical consumption, power usage, and hazardous sludge generation.

The company adheres to current Good Manufacturing Practice (cGMP) standards and norms set by international health authorities such as the US FDA, UK MHRA, and Australian TGA. Air emissions are monitored by M/s. Sadekar Enviro Engineering Pvt. Ltd., an external agency. The report notes a considerable reduction in NOx and Particulate Matter air emissions, as well as Scope 1 greenhouse gas emissions, compared to previous periods.

Employee Welfare and Social Impact

As of March 31, 2026, Marksans Pharma employed 1,685 permanent employees and workers, including 160 women. The Board of Directors comprises eight members, with two women representing 25% of the board. The company reports a 100% return-to-work rate for permanent employees who took parental leave. No complaints related to child labor, forced labor, or sexual harassment were received during the year.

The company’s Corporate Social Responsibility (CSR) initiatives focus on health and education in Goa, including free health check-up camps, distribution of medicines to underprivileged communities, and support for women and child development programs. Marksans Pharma also engages with stakeholders through regular communication channels, ensuring transparency in business practices and adherence to human rights policies.

Marksans Pharma Limited reported its highest-ever profitability for FY26, with consolidated revenue crossing the ₹3,000 crore mark to reach ₹3,033 crore and profit after tax (PAT) rising to ₹420 crore. The pharmaceutical company’s performance was driven by a 24% year-on-year surge in North American sales and significant margin expansion, culminating in an EBITDA of ₹601 crore with a margin of 20.4%. This financial strength has enabled the Board of Directors to recommend a final dividend of ₹0.90 per equity share, subject to shareholder approval at the 34th Annual General Meeting (AGM) on August 27, 2026.

The Board meeting held on May 26, 2026, also approved the re-appointment of Mrs. Sandra Saldanha as Whole-time Director for three years, effective September 25, 2026. Her proposed annual remuneration is ₹72,17,928. Additionally, Dr. Sunny Sharma retires by rotation and offers himself for re-appointment. The AGM will be conducted exclusively via Video Conferencing (VC) or Other Audio Visual Means (OAVM), with remote e-voting open from August 24 to August 26, 2026.

Financial Performance Highlights

Marksans Pharma’s FY26 results reflect robust operational execution and disciplined cost management. Operating revenue grew by 12.5% to ₹2,951 crore, while gross profit increased by 13.2% to ₹1,674 crore, pushing the gross margin to 56.7%. The company generated operating cash flows of ₹458 crore and free cash flows of ₹328 crore, ending the year with cash reserves of approximately ₹990 crore and maintaining a debt-free balance sheet.

| Metric | FY26 Value | YoY Change | | ---: | :--- | | Consolidated Revenue | ₹3,033 crore | ~12.5% | | Profit After Tax (PAT) | ₹420 crore | Highest ever | | EBITDA | ₹601 crore | Margin: 20.4% | | Operating Cash Flow | ₹458 crore | N/A | | Cash & Equivalents | ₹990 crore | N/A |

Geographic Growth Drivers

North America remained the largest and fastest-growing market, contributing approximately 52% of total revenue. Sales in this region grew by 24% to ₹1,533 crore, supported by the launch of 112 new SKUs and strong market share gains. The United Kingdom business also showed resilience, delivering record quarterly revenue in Q4FY26 after a challenging start to the year. Meanwhile, the Australia and New Zealand segment grew by 20% to ₹303 crore, bolstered by the strategic entry into the prescription segment through Nova Pharma.

What the Numbers Show

The divergence between revenue growth (12.5%) and gross profit growth (13.2%) indicates improved operating leverage and favorable product mix shifts. With EBITDA margins expanding to 20.4% from lower levels in previous periods, Marksans Pharma is successfully transitioning from volume-driven growth to value-driven profitability. The debt-free status combined with ₹990 crore in cash provides substantial flexibility for future R&D investments, which stood at ₹89 crore in FY26, or approximately 3% of consolidated revenue. This capital position supports the company’s strategic roadmap of filing over 200 products in the UK market over the next four years.

Dividend and Shareholder Details

The recommended final dividend of ₹0.90 per share represents a total cash outflow of ₹407.85 million. The record date for dividend entitlement is August 20, 2026, with payment scheduled on or after September 8, 2026. Shareholders must ensure their KYC and bank details are updated to receive electronic dividends. Unclaimed dividends from FY2018-19 will be transferred to the Investor Education and Protection Fund (IEPF) by November 1, 2026, urging shareholders to claim pending amounts promptly.